Poly Medicure Ltd.
Snapshot View

View in App

Prices View details

981.00 -11.20 ▼-1.1%

30 July 2021, 04:00:00 P.M.
Volume: 2,349

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.polymedicure.com
Financial Indicators
Market Cap 9,418.83 Cr.
Earnings per share (EPS) 15.31 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 64.18 Trailing Twelve Months Ending 2021-06
Industry PE - Trailing Twelve Months Ending 2021-06
Book Value / Share 104.56 Trailing Twelve Months Ending 2021-06
Price to Book Value 9.40 Calculated using Price: 982.35
Dividend Yield 0.25 Period Ending 2020-03
No. of Shares Subscribed 9.59 Cr. 95,880,567 Shares
FaceValue 5
Company Profile

Poly Medicure Ltd. was conceived and established by a group of engineers and technocrats dedicated to the idea of providing the benefits of modern healthcare to the mankind at affordable price. This unique philosophy has been the driving force behind the company since its inception in 1995. Today it has grown into one of the most dynamically versatile manufacturers of disposable healthcare products in the region with over 60 different products.

POLYMED manufactures its products using state of the art technology in ultra modern facilities covering over 300,000 square feet of manufacturing floor space with about 50,000 square feet of clean rooms of class 100,000 to class 1,000. A tool room with modern facilities & CNC machines supports the manufacturing processes. A high degree of automation and an effective process control helps in delivering consistent product quality.

To keep pace with the ever changing requirements of the market, POLYMED has a fully staffed and highly equipped R & D section to design and develop new and innovative products. Using the latest CAD/CAM technology, the new product development is fast and improvements, based on market response and customer feedback, are made with ease. Assuring world class products at affordable prices is the hall mark of POLYMED

Product range of the company:

The company manufactures different products related to :

  • Infusion Therapy
  • Central Venous Access Catheters
  • Anaesthesia
  • Urology
  • Gastroenterology
  • Blood Management
  • Surgery & Wound Drainage
  • Dialysis
  • Others

Achievements/ recognition:

  • QMS (Quality Management System) accredited by SGS
  • ISO 9001:2000
  • ISO-13485:2003
  • CE mark from DNV
  • US FDA 510k approved  

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.13%
1 Week
-2.42%
1 Month
-3.55%
3 Month
-1.37%
6 Month
+93.68%
1 Year
+148.95%
2 Year
+460.41%
5 Year
+374.07%

Ratios View Details

9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 22.40 22.63 34.10 36.03 22.35 21.81 22.76 17.80 22.98
Return on Capital Employed (%) 28.27 26.73 38.77 38.90 25.59 24.37 25.39 22.19 24.43
Return on Assets (%) 11.47 11.75 17.59 18.97 12.64 12.92 13.58 10.27 12.66

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 94 112 146 196 229 272 338 381 435
Non Curr. Liab. 27 34 51 55 49 72 104 119 135
Curr. Liab. 61 68 89 113 109 114 123 181 229
Minority Int. 0
Equity & Liab. 182 214 286 364 387 457 565 682 800
Non Curr. Assets 101 120 166 205 217 252 310 352 450
Curr. Assets 81 94 120 160 171 205 255 329 350
Misc. Exp. not W/O
Total Assets 182 214 286 364 387 457 565 682 800

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 217 260 322 390 412 455 520 611 687
Other Income 1 0 1 8 8 14 14 18 18
Total Income 218 260 323 398 421 469 535 629 706
Total Expenditure -169 -207 -247 -304 -325 -362 -398 -480 -521
PBIDT 48 53 77 94 96 107 136 150 185
Interest -8 -7 -9 -10 -10 -9 -12 -14 -20
Depreciation -12 -13 -14 -19 -21 -24 -29 -37 -41
Taxation -10 -10 -19 -23 -18 -20 -26 -35 -30
Exceptional Items 10 20
PAT 19 23 44 62 47 55 69 64 94

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 33 39 66 63 63 56 75 106 131
Cash Fr. Inv. -26 -31 -58 -59 -31 -56 -88 -101 -109
Cash Fr. Finan. -6 -8 5 -6 -31 0 16 -5 -21
Net Change 0 0 13 -2 1 0 3 1 1
Cash & Cash Eqvt 1 1 14 12 13 1 4 4 5

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 48.75 48.75 48.76 48.76 48.76 48.76 48.77 44.88 44.77
Public 51.25 51.25 51.24 51.24 51.24 51.24 51.23 55.12 55.23
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company<BR> Ref: Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations 2015 <BR>
Dear Sir/Madam

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations 2015 We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 29th July 2021 at 232-B 3RD Floor Okhla Industrial Estate Phase-III New Delhi - 110020 approved the enclosed businesses.
Thu, 29 Jul 2021
Unaudited Quarterly Financial Results(Standalone & Consolidated) For The Quarter Ended 30.06.2021.
Dear Sir/Madam

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations 2015 We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 29th July 2021 at 232-B 3RD Floor Okhla Industrial Estate Phase-III New Delhi - 110020 approved the enclosed businesses.
Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dear Sir/Madam
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an earnings call will be held on Friday 30th July 2021 at 3.00 p.m. (IST) for discussing the Audited Financial Results of the Company for the quarter ended 30th June 2021.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Closing Near 50 EMA Closing Near 50 EMA

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%